Unicycive is focused on two kidney diseases with large unmet medical needs. The company is developing Renazorb, an investigational phosphate binding agent using proprietary nanoparticle technology for the treatment of patients with hyperphosphatemia. Unicycive plans to file a New Drug Application (NDA) for Renazorb with the U.S. Food and Drug Administration (FDA) mid-year. Unicycive is also developing UNI-494, a new chemical entity with a novel mechanism of action that restores mitochondrial function in acute and chronic diseases. The company's initial target for UNI-494 is acute kidney injury (AKI), for which there are currently no FDA-approved medicines.